RT Journal Article
SR Electronic
T1 Evaluation of EUROSCORE II to determine the prognosis of patients with moderate-to-severe aortic stenosis: a long-term retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.23.24312516
DO 10.1101/2024.08.23.24312516
A1 Cai, Xianzhen
A1 Hu, Danchun
A1 Yan, Baoxin
A1 Chen, Jinhao
A1 Li, Weiwen
A1 Lin, Ying
A1 Lin, Run
A1 Ye, Junjun
A1 Huang, Xiaojun
A1 Xie, Bin
A1 Zhuang, Xiaodong
A1 Chen, Jianying
A1 Li, Jilin
YR 2024
UL http://medrxiv.org/content/early/2024/08/26/2024.08.23.24312516.abstract
AB Background and Aims Aortic stenosis (AS) was a prevalent heart valve disease whose morbidity and mortality can be reduced by aortic valve replacement (AVR) . EUROSCORE II assesses the perioperative mortality of severe AS patients undergoing AVR. This study explored EUROSCORE II’s prognostic value for long-term all-cause mortality of Chinese patients with moderate-to-severe AS and determined whether AVR affects this.Methods Allocated to four groups following the EUROSCORE II (cut-off value of 4%) and whether performed AVR, 544 patients with moderate-to-severe AS were enrolled. Baseline data, Kaplan–Meier, Cox regression and subgroup analysis were used to analyse the relationship between EUROSCORE II and participants’ all-cause mortality. Furthermore, ROC analysis determining the optimal cut-off value of EUROSCORE II was utilized.Results During a median follow-up of 41.4 months, 177 (21.5%) participants reached the endpoint, with higher risks (EUROSCORE II ≥4%) and no AVR exhibited significantly increased all-cause mortality rates compared to other groups (55.4% vs. 6.5%, 13.4%, and 32.7%; P<0.001). Kaplan-Meier curves confirmed these findings (log-rank test P<0.001). Cox regression analysis revealed a 6.891-fold higher risk (HR, 6.891; 95% CI, 3.083-15.401; P<0.001) in patients without AVR with higher EUROSCORE II. The adjusted model (P<0.01) and subgroup analyses (without AVR P=0.001; with AVR P=0.029) supported EUROSCORE II’s prognostic value for all-cause mortality. The optimal EUROSCORE II cut-off for predicting all-cause mortality in patients without AVR was 2.23% (AUC 0.675).Conclusions EUROSCORE II (cut-off value 4%) and AVR independently impact the long-term prognosis of patients with moderate-to-severe AS.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialPre-registered clinical trial number: NCT06069232.Funding StatementNothing to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Review Committee of the Second Affiliated Hospital of Shantou University Medical College(ERB number: ethics form 9-5).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding authors upon reasonable request.